Irina M. Patrikeeva
Irina M. Patrikeeva has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Elena E. Gubar
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - Elena Yu. Loginova
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
8 shared publications - Tatiana V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - Yuliia L. Korsakova
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
6 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 23 (3) , 708-714
Experience in Treating Dry Eye Syndrome in Autoimmune Diseases
Objective — to evaluate the effect of combined treatment on diagnostic tests of dry eye syndrome in patients with rheumatic diseases. Material and methods. Prospectively examined 80 patients with rheumatic diseases receiving basic gene-engineered therapy. With rheumatoid arthritis with ankylosing spondylitis 50 patients and 30 respectively. When the diagnostic criteria of dry eye syndrome were identified, patients were prescribed СФЕРО®око. Results. In patients with rheumatic diseases, a total production disorder was detected in 65 % of OD and 63.75 % of OS. In patients with rheumatoid arthritis, this pathology was detected in 74 % and 70 %, respectively, and in patients with ankylosing spondylitis, it was detected in 53.3 % of cases, with no severe damage and almost equal numbers of mild and moderate damage. In every second patient on OD and slightly more on OS, tear film stability disorders were detected. The results of the Shirmer and Norn tests are affected by the hemogram, the duration of the disease, and the patient’s age. Conclusion. The use of SPHERO®oko has been shown to be effective in treating dry eye syndrome in patients with rheumatoid arthritis and ankylosing spondylitis who are receiving gene therapy. Additional administration of SPHERO®oko topical therapy leads to normalization of the Schirmer test results (in every second case on OD and in 62.8 % of cases on OS), and a decrease in tear film instability to 33.3 % OD and 14 % OS in rheumatoid arthritis, and 26.6 % OD and 26.3 % OS in ankylosing spondylitis. Conclusion. The use of SPHERO®oko has been shown to be effective in the treatment of dry eye syndrome in patients with rheumatoid arthritis and ankylosing spondylitis who are receiving gene therapy.
- 5 October 2026
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 23 (3) , 708-714
Open AccessExperience in Treating Dry Eye Syndrome in Autoimmune Diseases
Objective — to evaluate the effect of combined treatment on diagnostic tests of dry eye syndrome in patients with rheumatic diseases. Material and methods. Prospectively examined 80 patients with rheumatic diseases receiving basic gene-engineered therapy. With rheumatoid arthritis with ankylosing spondylitis 50 patients and 30 respectively. When the diagnostic criteria of dry eye syndrome were identified, patients were prescribed СФЕРО®око. Results. In patients with rheumatic diseases, a total production disorder was detected in 65 % of OD and 63.75 % of OS. In patients with rheumatoid arthritis, this pathology was detected in 74 % and 70 %, respectively, and in patients with ankylosing spondylitis, it was detected in 53.3 % of cases, with no severe damage and almost equal numbers of mild and moderate damage. In every second patient on OD and slightly more on OS, tear film stability disorders were detected. The results of the Shirmer and Norn tests are affected by the hemogram, the duration of the disease, and the patient’s age. Conclusion. The use of SPHERO®oko has been shown to be effective in treating dry eye syndrome in patients with rheumatoid arthritis and ankylosing spondylitis who are receiving gene therapy. Additional administration of SPHERO®oko topical therapy leads to normalization of the Schirmer test results (in every second case on OD and in 62.8 % of cases on OS), and a decrease in tear film instability to 33.3 % OD and 14 % OS in rheumatoid arthritis, and 26.6 % OD and 26.3 % OS in ankylosing spondylitis. Conclusion. The use of SPHERO®oko has been shown to be effective in the treatment of dry eye syndrome in patients with rheumatoid arthritis and ankylosing spondylitis who are receiving gene therapy.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Resolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Open AccessResolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 15-23
Non-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 15-23
Open AccessNon-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.
- Open Access
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 44-53
Direct interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis
Interleukin (IL)-6 is a key mediator in the pathogenesis of rheumatoid arthritis (RA). Olokizumab (OKZ, Artlegia®, R-Pharm) is a direct IL-6 inhibitor whose efficacy has been demonstrated in randomized controlled trials, post-marketing studies, and real-world practice. However, different dosing regimens of OKZ and their impact on its usage frequency, as well as on doses of glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs), have been insufficiently studied. Objective: to evaluate the efficacy and safety of OKZ in routine clinical practice, with emphasis on the use of different dosing regimens and concomitant use of GCs and NSAIDs in patients with RA. Material and methods. In a multicenter retrospective observational program included patients in whom OKZ therapy was initiated in real-world clinical practice from 01.12.2023 to 30.11.2024 with subsequent 12-month follow-up. A total of 1240 adult patients with active RA meeting the 2010 ACR/EULAR criteria were enrolled. Of these, 80.5% were women; median age was 55 years; median RA duration was 87 months; 86.5% of patients were rheumatoid factor positive, 82.7% were positive for anti-cyclic citrullinated peptide antibodies; a high comorbidity burden was noted. Patients with incomplete DAS28-CRP/CDAI data or follow-up Results and discussion. At baseline, 89.4% of patients had high/moderate RA activity according to DAS28-CRP. OKZ was prescribed once every 4 weeks in 89.8% of cases; in patients with higher laboratory activity, once every 2 weeks in 10.2% (pConclusion. In the vast majority of cases, OKZ is used at a dose of 64 mg once every 4 weeks, providing achievement of therapeutic targets in real-world clinical practice in most patients (by month 12 – in 78.4%). In our observation trial the proportion of patients who require every 2 week administration was insignificant and included no more than 3% over 12 months of therapy. Therapy is accompanied by a significant reduction in the need for GCs and NSAIDs.
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 44-53
Open AccessDirect interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis
Interleukin (IL)-6 is a key mediator in the pathogenesis of rheumatoid arthritis (RA). Olokizumab (OKZ, Artlegia®, R-Pharm) is a direct IL-6 inhibitor whose efficacy has been demonstrated in randomized controlled trials, post-marketing studies, and real-world practice. However, different dosing regimens of OKZ and their impact on its usage frequency, as well as on doses of glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs), have been insufficiently studied. Objective: to evaluate the efficacy and safety of OKZ in routine clinical practice, with emphasis on the use of different dosing regimens and concomitant use of GCs and NSAIDs in patients with RA. Material and methods. In a multicenter retrospective observational program included patients in whom OKZ therapy was initiated in real-world clinical practice from 01.12.2023 to 30.11.2024 with subsequent 12-month follow-up. A total of 1240 adult patients with active RA meeting the 2010 ACR/EULAR criteria were enrolled. Of these, 80.5% were women; median age was 55 years; median RA duration was 87 months; 86.5% of patients were rheumatoid factor positive, 82.7% were positive for anti-cyclic citrullinated peptide antibodies; a high comorbidity burden was noted. Patients with incomplete DAS28-CRP/CDAI data or follow-up Results and discussion. At baseline, 89.4% of patients had high/moderate RA activity according to DAS28-CRP. OKZ was prescribed once every 4 weeks in 89.8% of cases; in patients with higher laboratory activity, once every 2 weeks in 10.2% (pConclusion. In the vast majority of cases, OKZ is used at a dose of 64 mg once every 4 weeks, providing achievement of therapeutic targets in real-world clinical practice in most patients (by month 12 – in 78.4%). In our observation trial the proportion of patients who require every 2 week administration was insignificant and included no more than 3% over 12 months of therapy. Therapy is accompanied by a significant reduction in the need for GCs and NSAIDs.
- Open Access
- 29 December 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (6) , 598-603
Resistant to therapy psoriatic arthritis. Data from Russian Registry of psoriatic arthritis patients
The aim – to identify clinical characteristics of resistant to therapy psoriatic arthritis (PsA) patients. Material and methods . 459 patients (M/F=213/246), mean age 46.1±12.5 years (yrs) with PsA treated by biologic or target synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) within 2 yrs were included. Difficultto-treat (D2T) PsA was defined as failure of ≥2 b/tsDMARDs with different mechanism of action among tumor necrosis factor (TNF) inhibitors, anti-interleukin (IL) 17, anti-IL12/23, anti-IL13 and Janus kinase (JAK) inhibitors within 2 yrs of follow-up. Complex-to-manage (C2M) PsA was defined as failure of ≥2 b/tsDMARDs and includes additional factors such as lack of access to treatment or contraindication or intolerance. D2T and C2M patient’s characteristics were compared with each other and with responders to therapy (non-D2T) patients using statistical tests. Results. 352 (76.7%) patients (M/F=163/189) responded to the first b/tsDMARDs. 107 (23.3%) patients were resistant to treatment. Of these, 53 (11.5% of all those included in the study) (M/F=26/27) were identified as D2T and 54 (11.8%) (M/F=24/30) as C2M. A comparative analysis performed of 107 resistant and 352 responding patients with PsA showed that PsA-resistant patients had a significantly more often enthesitis 31% vs 17% (p=0.002), dactylitis 34% vs 20% (p=0.004), depression 30% vs 19% (p=0.002), cardiovascular diseases 28% vs 40% (р=0.031) and ≥2 comorbidities 39% vs 51% (р=0.045), than those who responded to treatment. A comparative analysis performed of 54 C2M PsA and 53 D2T PsA showed that C2M patients had a significantly more often pain/discomfort 43% vs 19% (p=0.024) and depression 41% vs 19% (p=0.04), significantly less often enthesitis 15% vs 47% (p=0.001) and dactylitis 24% vs 43% (р=0.04) than D2T PsA. Conclusions. In real clinical practice treatment-resistant PsA patients occur in quarter (23.3%) cases, of them D2T PsA patients – in 11.5% and C2M – in 11.8% cases. Treatment-resistant PsA patients compared with responders to therapy are characterized by presence of enthesitis, dactylitis and various comorbidities mainly depression and cardiovascular disease. C2M PsA patients compared with D2T PsA are characterized by presence of pain/discomfort and depression.
- 29 December 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (6) , 598-603
Open AccessResistant to therapy psoriatic arthritis. Data from Russian Registry of psoriatic arthritis patients
The aim – to identify clinical characteristics of resistant to therapy psoriatic arthritis (PsA) patients. Material and methods . 459 patients (M/F=213/246), mean age 46.1±12.5 years (yrs) with PsA treated by biologic or target synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) within 2 yrs were included. Difficultto-treat (D2T) PsA was defined as failure of ≥2 b/tsDMARDs with different mechanism of action among tumor necrosis factor (TNF) inhibitors, anti-interleukin (IL) 17, anti-IL12/23, anti-IL13 and Janus kinase (JAK) inhibitors within 2 yrs of follow-up. Complex-to-manage (C2M) PsA was defined as failure of ≥2 b/tsDMARDs and includes additional factors such as lack of access to treatment or contraindication or intolerance. D2T and C2M patient’s characteristics were compared with each other and with responders to therapy (non-D2T) patients using statistical tests. Results. 352 (76.7%) patients (M/F=163/189) responded to the first b/tsDMARDs. 107 (23.3%) patients were resistant to treatment. Of these, 53 (11.5% of all those included in the study) (M/F=26/27) were identified as D2T and 54 (11.8%) (M/F=24/30) as C2M. A comparative analysis performed of 107 resistant and 352 responding patients with PsA showed that PsA-resistant patients had a significantly more often enthesitis 31% vs 17% (p=0.002), dactylitis 34% vs 20% (p=0.004), depression 30% vs 19% (p=0.002), cardiovascular diseases 28% vs 40% (р=0.031) and ≥2 comorbidities 39% vs 51% (р=0.045), than those who responded to treatment. A comparative analysis performed of 54 C2M PsA and 53 D2T PsA showed that C2M patients had a significantly more often pain/discomfort 43% vs 19% (p=0.024) and depression 41% vs 19% (p=0.04), significantly less often enthesitis 15% vs 47% (p=0.001) and dactylitis 24% vs 43% (р=0.04) than D2T PsA. Conclusions. In real clinical practice treatment-resistant PsA patients occur in quarter (23.3%) cases, of them D2T PsA patients – in 11.5% and C2M – in 11.8% cases. Treatment-resistant PsA patients compared with responders to therapy are characterized by presence of enthesitis, dactylitis and various comorbidities mainly depression and cardiovascular disease. C2M PsA patients compared with D2T PsA are characterized by presence of pain/discomfort and depression.
- Open Access
- 2 July 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (3) , 273-278
Prognosis of pharmacotherapy effectiveness in psoriatic arthritis
The aim – to develop a method for predicting the effectiveness of psoriatic arthritis (PsA) therapy.Methods. 377 PsA patients (pts) were examined: (М/F 185/192). Pts’ age 47.6±12.4 years, psoriasis (PsO) duration 206.8±156.3 months, PsA duration – 84.8±84.6 months. Pts underwent standard clinical examination, the analysis included detection of comorbidities according to ICD-10. Pts were evaluated for achieving minimal disease activity (MDA). Data of visit 2 (6 months of treatment) were analysed.Results. At 6 months of treatment tender joint count was 3,0 [0.0; 8.0], swollen joint count – 1,0 [0.0; 5.0], C-reactive protein (CRP) – 4,3 (0.0–90.6) mg/l, LEI (Leeds Enthesitis Index) – 0,0 (0.0–6.0), body mass index (BMI) – 27.6±5.2 kg/m2. 273 (72%) pts had BMI2, 75 (19.9%) pts – 30≤ BMI2, 29 (7.7%) pts – BMI≥35 kg/m2. Mild PsO (BSA≤3%) was found in 264 (70.0%) of 377 pts, moderate (3%10%) – in 17 (4.5%) pts. 82 (21.8%) pts met the MDA criteria. Comorbid diseases were found in 152 (40%) pts.Multivariate analysis was performed and the following parameters were revealed that negatively correlate with MDA achievement – CRP (p=0.0001), LEI (p=0.001), arterial hypertension (AH) (p=0.08), BSA (p=0.063), BMI (p=0.289). A discriminant rule was obtained that makes it possible to predict the possibility of MDA achievement: 0.046×(CRP, mg/l) + 0.470×LEI + 0.527×(AH) + 0.451×(BSA) + 0.237×(BMI) ≤1.184.This formula includes the values of CRP, LEI, AH (no AH – 0 points, with AH – 1 point), BSA (BSA≤3% – 1 point, 3%10% – 3 points), BMI (BMI2 – 0, 30≤BMI2 – 1 point, BMI≥35 kg/m2 – 2 points). When the expression value is ≤1.184, the achievement of MDA in PsA pts is predicted.The area under the ROC curve is 0.76, which makes it possible to estimate the predictive accuracy of the model as high (95% CI: 0.71–0.81; p=0.26. For the selected total value of the discriminant function 1.184, sensitivity is 85.4%, specificity – 59.3%.Conclusion. The developed method for predicting the MDA achievement in PsA pts including the following indicators: CRP, LEI, the presence of hypertension and obesity, severity of PsO – makes it possible to predict the treatment outcome in PsA pts and stimulates both the physician and the patient to modify the factors included in this formula.
- 2 July 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (3) , 273-278
Open AccessPrognosis of pharmacotherapy effectiveness in psoriatic arthritis
The aim – to develop a method for predicting the effectiveness of psoriatic arthritis (PsA) therapy.Methods. 377 PsA patients (pts) were examined: (М/F 185/192). Pts’ age 47.6±12.4 years, psoriasis (PsO) duration 206.8±156.3 months, PsA duration – 84.8±84.6 months. Pts underwent standard clinical examination, the analysis included detection of comorbidities according to ICD-10. Pts were evaluated for achieving minimal disease activity (MDA). Data of visit 2 (6 months of treatment) were analysed.Results. At 6 months of treatment tender joint count was 3,0 [0.0; 8.0], swollen joint count – 1,0 [0.0; 5.0], C-reactive protein (CRP) – 4,3 (0.0–90.6) mg/l, LEI (Leeds Enthesitis Index) – 0,0 (0.0–6.0), body mass index (BMI) – 27.6±5.2 kg/m2. 273 (72%) pts had BMI2, 75 (19.9%) pts – 30≤ BMI2, 29 (7.7%) pts – BMI≥35 kg/m2. Mild PsO (BSA≤3%) was found in 264 (70.0%) of 377 pts, moderate (3%10%) – in 17 (4.5%) pts. 82 (21.8%) pts met the MDA criteria. Comorbid diseases were found in 152 (40%) pts.Multivariate analysis was performed and the following parameters were revealed that negatively correlate with MDA achievement – CRP (p=0.0001), LEI (p=0.001), arterial hypertension (AH) (p=0.08), BSA (p=0.063), BMI (p=0.289). A discriminant rule was obtained that makes it possible to predict the possibility of MDA achievement: 0.046×(CRP, mg/l) + 0.470×LEI + 0.527×(AH) + 0.451×(BSA) + 0.237×(BMI) ≤1.184.This formula includes the values of CRP, LEI, AH (no AH – 0 points, with AH – 1 point), BSA (BSA≤3% – 1 point, 3%10% – 3 points), BMI (BMI2 – 0, 30≤BMI2 – 1 point, BMI≥35 kg/m2 – 2 points). When the expression value is ≤1.184, the achievement of MDA in PsA pts is predicted.The area under the ROC curve is 0.76, which makes it possible to estimate the predictive accuracy of the model as high (95% CI: 0.71–0.81; p=0.26. For the selected total value of the discriminant function 1.184, sensitivity is 85.4%, specificity – 59.3%.Conclusion. The developed method for predicting the MDA achievement in PsA pts including the following indicators: CRP, LEI, the presence of hypertension and obesity, severity of PsO – makes it possible to predict the treatment outcome in PsA pts and stimulates both the physician and the patient to modify the factors included in this formula.
- Open Access
- 15 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 57-63
Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
The Tyumen Regional Rheumatology Center has gained experience in the use of the interleukin-6 inhibitor olokizumab (OKZ) in the treatment of patients with rheumatoid arthritis (RA).Objective: to evaluate the efficacy and safety of OKZ therapy in patients with RA in real-life clinical practice.Material and methods. The analysis included 75 patients with a confirmed diagnosis of RA who were prescribed OKZ at a dose of 64 mg every 4 weeks. All patients underwent a standard clinical and laboratory examination and concomitant diseases were recorded. The results were evaluated after 1, 6 and 12 months of therapy. A retrospective evaluation of radiological outcomes was performed in 20 patients who had received OKZ for at least 1 year.Results and discussion. After only one month of OKZ treatment, the proportion of patients with high RA activity according to DAS28-CRP decreased statistically significantly from 81% to 53.3%. After 6 months, 55 (73.33%) of 75 patients continued OKZ therapy, and most of them (74.55%) achieved the stage of drug remission, while high RA activity was not detected. After 12 months, 43 (57.33%) of the 75 patients continued OKZ therapy, with low activity and remission observed in 16.2 and 69.8% of them, respectively. During these periods, there was no radiological progression of RA against the background of OKZ therapy. Ten patients (13.33%) discontinued OKZ therapy due to insufficient efficacy, 2 (2.67%) due to pregnancy, 14 (18.67%) due to adverse events and 6 (8%) for other reasons.Conclusion. In real-world clinical practice, OKZ showed significant therapeutic potential and a favorable safety profile in patients with RA.
- 15 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 57-63
Open AccessExperience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
The Tyumen Regional Rheumatology Center has gained experience in the use of the interleukin-6 inhibitor olokizumab (OKZ) in the treatment of patients with rheumatoid arthritis (RA).Objective: to evaluate the efficacy and safety of OKZ therapy in patients with RA in real-life clinical practice.Material and methods. The analysis included 75 patients with a confirmed diagnosis of RA who were prescribed OKZ at a dose of 64 mg every 4 weeks. All patients underwent a standard clinical and laboratory examination and concomitant diseases were recorded. The results were evaluated after 1, 6 and 12 months of therapy. A retrospective evaluation of radiological outcomes was performed in 20 patients who had received OKZ for at least 1 year.Results and discussion. After only one month of OKZ treatment, the proportion of patients with high RA activity according to DAS28-CRP decreased statistically significantly from 81% to 53.3%. After 6 months, 55 (73.33%) of 75 patients continued OKZ therapy, and most of them (74.55%) achieved the stage of drug remission, while high RA activity was not detected. After 12 months, 43 (57.33%) of the 75 patients continued OKZ therapy, with low activity and remission observed in 16.2 and 69.8% of them, respectively. During these periods, there was no radiological progression of RA against the background of OKZ therapy. Ten patients (13.33%) discontinued OKZ therapy due to insufficient efficacy, 2 (2.67%) due to pregnancy, 14 (18.67%) due to adverse events and 6 (8%) for other reasons.Conclusion. In real-world clinical practice, OKZ showed significant therapeutic potential and a favorable safety profile in patients with RA.
- 20 December 2024
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 16 (4) , 104-110
Efficacy of conservative treatment of chronic multiple nonbacterial osteomyelitis in adults based on one-year follow-up results
BACKGROUND: Chronic multiple nonbacterial osteomyelitis is an orthopaedic autoinflammatory disease of bones and joints of unclear aetiology, characterised by the formation of multiple foci of osteitis refractory to antibiotic therapy and surgical treatment, occurring predominantly before the age of 18 years. Data on the treatment of adult chronic multiple nonbacterial osteomyelitis are limited due to the orphan character of the disease and the rarity of its onset in adults. AIM: To present data on the efficacy of conservative treatment of adult chronic multiple nonbacterial osteomyelitis after one-year follow-up. MATERIALS AND METHODS: 12 patients aged 18 years and older with a histologically confirmed diagnosis of chronic multiple nonbacterial osteomyelitis were followed up. Clinical, demographic and laboratory data of the patients were recorded. RESULTS: The sex and age structure of the studied group of the patients: 7 women (58.33%), 5 men (41.67%); the average age of the patients was 37.35 ± 15.5 years. Monofocal forms of chronic multiple nonbacterial osteomyelitis were observed in 8 cases (66.67%), multifocal – in 4 cases (33.33%). Drug therapy in the study group: all the patients (100%) received non-steroidal anti-inflammatory drugs, 3 patients (25.0%) received glucocorticosteroids per os; cytostatics – by 7 patients (58.33%), bisphosphonates – by 3 patients (25.0%), genetically engineered biological therapy – by 5 patients (41.67%). Therapeutic treatment of chronic multiple nonbacterial osteomyelitis was started after surgical treatment in 6 patients (50.0%); in 6 patients (50.0%) conservative treatment was prescribed immediately after diagnosis. The conservative treatment was effective: after the beginning of adequate drug therapy; no surgical reatment was performed; stable clinical and laboratory remission of the disease without relapses of osteitis was observed. CONCLUSIONS: In a typical group of adult patients with chronic multiple nonbacterial osteomyelitis, conservative treatment with the use of immunosuppressive treatment allows to achieve control over the disease activity with the absence of osteitis recurrences during a year of observation.
- 20 December 2024
- Published by ECO-Vector LLC in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 16 (4) , 104-110
Efficacy of conservative treatment of chronic multiple nonbacterial osteomyelitis in adults based on one-year follow-up results
BACKGROUND: Chronic multiple nonbacterial osteomyelitis is an orthopaedic autoinflammatory disease of bones and joints of unclear aetiology, characterised by the formation of multiple foci of osteitis refractory to antibiotic therapy and surgical treatment, occurring predominantly before the age of 18 years. Data on the treatment of adult chronic multiple nonbacterial osteomyelitis are limited due to the orphan character of the disease and the rarity of its onset in adults. AIM: To present data on the efficacy of conservative treatment of adult chronic multiple nonbacterial osteomyelitis after one-year follow-up. MATERIALS AND METHODS: 12 patients aged 18 years and older with a histologically confirmed diagnosis of chronic multiple nonbacterial osteomyelitis were followed up. Clinical, demographic and laboratory data of the patients were recorded. RESULTS: The sex and age structure of the studied group of the patients: 7 women (58.33%), 5 men (41.67%); the average age of the patients was 37.35 ± 15.5 years. Monofocal forms of chronic multiple nonbacterial osteomyelitis were observed in 8 cases (66.67%), multifocal – in 4 cases (33.33%). Drug therapy in the study group: all the patients (100%) received non-steroidal anti-inflammatory drugs, 3 patients (25.0%) received glucocorticosteroids per os; cytostatics – by 7 patients (58.33%), bisphosphonates – by 3 patients (25.0%), genetically engineered biological therapy – by 5 patients (41.67%). Therapeutic treatment of chronic multiple nonbacterial osteomyelitis was started after surgical treatment in 6 patients (50.0%); in 6 patients (50.0%) conservative treatment was prescribed immediately after diagnosis. The conservative treatment was effective: after the beginning of adequate drug therapy; no surgical reatment was performed; stable clinical and laboratory remission of the disease without relapses of osteitis was observed. CONCLUSIONS: In a typical group of adult patients with chronic multiple nonbacterial osteomyelitis, conservative treatment with the use of immunosuppressive treatment allows to achieve control over the disease activity with the absence of osteitis recurrences during a year of observation.
- Open Access
- 14 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 32-43
Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL in RA patients. Objective: to evaluate the efficacy and safety of LVL in the treatment of patients with RA in real-world clinical practice. Materials and methods. The HELIOS study is a retrospective-prospective, multicenter, non-interventional study of retention rate of LVL therapy and the safety of LVL in patients with RA in real-world clinical practice. Patients received medical care, including LVL, according to routine clinical practice for the treatment of RA and Russian instructions for medical use of the drug. This article presents the results of an analysis of the efficacy and safety of LVL after 12 and 24 weeks of treatment. Efficacy was assessed using the DAS28-CRP/ESR, SDAI, CDAI and patient assessment of pain, fatigue and morning stiffness according to VAS (0–100 mm). Results and discussion. 524 patients from 42 medical centers in the Russian Federation were enrolled in the study from June 2022 to November 2023. The majority of patients were female (83.2 %) and the mean age of patients was 53 years. A statistically significant decrease in DAS28-CRP/ESR, SDAI, CDAI, patient assessment of pain, fatigue and morning stiffness (VAS) was observed after 12 and 24 weeks of treatment, regardless of previous treatment with biologics or Jak inhibitors (JAKi). LVL was well tolerated by patients, the most frequently reported adverse events were infections, changes in peripheral blood and laboratory abnormalities characteristic of treatment with IL-6R inhibitors. Conclusion. In real-world clinical practice, LVL has been shown to be highly effective and well tolerated in patients with RA when prescribed as the first biologic disease-modifying antirheaumatic drus (bDMARD) and after switching from other bDMARDs or JAKi.
- 14 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 32-43
Open AccessEfficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL in RA patients. Objective: to evaluate the efficacy and safety of LVL in the treatment of patients with RA in real-world clinical practice. Materials and methods. The HELIOS study is a retrospective-prospective, multicenter, non-interventional study of retention rate of LVL therapy and the safety of LVL in patients with RA in real-world clinical practice. Patients received medical care, including LVL, according to routine clinical practice for the treatment of RA and Russian instructions for medical use of the drug. This article presents the results of an analysis of the efficacy and safety of LVL after 12 and 24 weeks of treatment. Efficacy was assessed using the DAS28-CRP/ESR, SDAI, CDAI and patient assessment of pain, fatigue and morning stiffness according to VAS (0–100 mm). Results and discussion. 524 patients from 42 medical centers in the Russian Federation were enrolled in the study from June 2022 to November 2023. The majority of patients were female (83.2 %) and the mean age of patients was 53 years. A statistically significant decrease in DAS28-CRP/ESR, SDAI, CDAI, patient assessment of pain, fatigue and morning stiffness (VAS) was observed after 12 and 24 weeks of treatment, regardless of previous treatment with biologics or Jak inhibitors (JAKi). LVL was well tolerated by patients, the most frequently reported adverse events were infections, changes in peripheral blood and laboratory abnormalities characteristic of treatment with IL-6R inhibitors. Conclusion. In real-world clinical practice, LVL has been shown to be highly effective and well tolerated in patients with RA when prescribed as the first biologic disease-modifying antirheaumatic drus (bDMARD) and after switching from other bDMARDs or JAKi.